N. Kalkers

发表

Long-term clinical outcome of primary progressive MS: Predictive value of clinical and MRI data

F. Barkhof, M. Rovaris, M. Filippi, 2005, Neurology.

Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype.

F. Barkhof, C. Polman, N. Kalkers, 2002, Archives of neurology.

Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS

C. Polman, V. de Groot, N. Kalkers, 2004, Neurology.

The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study

F. Barkhof, C. Polman, R. V. van Schijndel, 2002, Multiple sclerosis.

Chemokine receptor expression on T cells is related to new lesion development in multiple sclerosis

F. Barkhof, C. Polman, B. Uitdehaag, 2002, Journal of Neuroimmunology.

Optimizing the association between disability and biological markers in MS

F Barkhof, C H Polman, F. Barkhof, 2001, Neurology.

Erratum: Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy (Journal of the Neurological Sciences 184 (2001) (155-162) PII: S0022510X01004312)

F. Barkhof, C. Polman, H. Adèr, 2001 .

Expression of adhesion molecules on peripheral lymphocytes predicts future lesion development in MS

F. Barkhof, C. Polman, B. Uitdehaag, 2005, Journal of Neuroimmunology.

Erratum to “Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy” [J. Neurol. Sci. 184 (2001) 155–162]

F. Barkhof, C. Polman, H. Adèr, 2001, Journal of the Neurological Sciences.

Patients with multiple sclerosis prefer early diagnosis

A. Janssens, J. Passchier, N. Kalkers, 2004, European journal of neurology.

Personalized extended interval dosing of natalizumab in MS

F. Barkhof, B. Uitdehaag, A. ten Brinke, 2020, Neurology.

The interleukin-1 gene family in multiple sclerosis susceptibility and disease course

F. Barkhof, C. Polman, D. Knol, 2003, Multiple sclerosis.

Production of IL-1β and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis

C. Polman, B. Uitdehaag, E. Bollen, 2002, Journal of Neuroimmunology.

The FAS−670 polymorphism influences susceptibility to multiple sclerosis

F. Barkhof, C. Polman, T. Veen, 2002, Journal of Neuroimmunology.

The Brief Repeatable Battery of Neuropsychological Tests: normative values allow application in multiple sclerosis clinical practice

C H Polman, C. Polman, J. Lindeboom, 2001, Multiple sclerosis.

Safety, tolerability, and efficacy of orally administered cannabinoids in MS

C. Polman, B. Uitdehaag, N. Kalkers, 2002, Neurology.

A longitudinal study of cognition in primary progressive multiple sclerosis.

A. Thompson, M. Filippi, X. Montalban, 2005, Brain : a journal of neurology.

Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional C omposite

F. Barkhof, C. Polman, J. Hobart, 2004, Multiple sclerosis.

Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy

F. Barkhof, C. H. Polman, F. Barkhof, 2001, Journal of the Neurological Sciences.

Determinants of cerebral atrophy rate at the time of diagnosis of multiple sclerosis.

Frederik Barkhof, Bernard M J Uitdehaag, Chris H Polman, 2007, Archives of neurology.

Neuroprotective Treatment in Primary Progressive Multiple Sclerosis: a Phase I/II Study with Riluzole

F. Barkhof, C. Polman, N. Kalkers, 2004 .

Concurrent validity of the MS Functional Composite using MRI as a biological disease marker

F. Barkhof, C. Polman, V. de Groot, 2001, Neurology.

MS Functional Composite

F Barkhof, V de Groot, J Killestein, 2000, Neurology.

TNFα production by CD4+ T cells predicts long-term increase in lesion load on MRI in MS

F. Barkhof, C. Polman, R. V. van Lier, 2001, Neurology.

Two-year follow-up study of primary and transitional progressive multiple sclerosis

M Rovaris, A J Thompson, F Barkhof, 2002, Multiple sclerosis.

αB-Crystallin genotype has impact on the multiple sclerosis phenotype

F. Barkhof, C. Polman, B. Uitdehaag, 2003, Neurology.

Cognitive impairment and decline in different MS subtypes

C. Polman, L. Sonneville, N. Kalkers, 2006, Journal of the Neurological Sciences.

Multiple sclerosis functional composite: impact of reference population and interpretation of changes

C. Polman, B. Uitdehaag, V. de Groot, 2002, Multiple sclerosis.

Responder rates to fampridine differ between clinical subgroups of MS patients and patient reported outcome influences treatment decision making.

B. Uitdehaag, N. Kalkers, J. Killestein, 2019, Multiple sclerosis and related disorders.

Production of IL-1beta and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis.

C. Polman, M. van Buchem, B. Uitdehaag, 2002, Journal of neuroimmunology.

Glutamate inhibition in MS: The neuroprotective properties of riluzole

C. Polman, N. Kalkers, J. Killestein, 2005, Journal of the Neurological Sciences.

Cross-sectional and longitudinal correlations between the Arm Function in Multiple Sclerosis Questionnaire (AMSQ) and other outcome measures in multiple sclerosis.

N. Kalkers, B. Uitdehaag, E. Strijbis, 2022, Multiple sclerosis and related disorders.

A nxiety and depression influence the relation between disability status and quality of life in multiple sclerosis

A. Janssens, J. Passchier, J. D. de Boer, 2003, Multiple sclerosis.

Differential item functioning of the Arm function in Multiple Sclerosis Questionnaire (AMSQ) by language, a study in six countries

X. Montalban, L. Mokkink, B. Uitdehaag, 2019, Multiple sclerosis.

Brain atrophy in multiple sclerosis: impact of lesions and of damage of whole brain tissue

F. Barkhof, H. Vrenken, C. Polman, 2002, Multiple sclerosis.

Motor evoked potential: A reliable and objective measure to document the functional consequences of multiple sclerosis? Relation to disability and MRI

C. Stam, F. Barkhof, C. Polman, 2007, Clinical Neurophysiology.

A study validating changes in the multiple sclerosis functional composite.

C. Polman, B. Uitdehaag, N. Kalkers, 2002, Archives of neurology.

The Multiple Sclerosis Data Alliance Catalogue: Enabling Web-Based Discovery of Metadata from Real-World Multiple Sclerosis Data Sources.

L. Leocani, W. van Hecke, M. Tintoré, 2021, International journal of MS care.

Differential treatment effect on measures of neurologic exam, functional impairment and patient self-report in multiple sclerosis

C. Polman, B. Uitdehaag, N. Kalkers, 2001, Multiple sclerosis.

Comparisons of patient self-report, neurologic examination, and functional impairment in MS

C. Polman, N. Kalkers, B. Uitdehaag, 2001, Neurology.

Autonomic Dysregulation, Cognitive Impairment, and Symptoms of Psychosis as an Unusual Presentation in an Anti-Aquaporin 4-Positive Patient

N. Kalkers, E. van Gorsel, A. Ruiter, 2017, Case Reports in Neurology.

Minimal clinically important difference of improvement on the Arm Function in Multiple Sclerosis Questionnaire (AMSQ)

B. Uitdehaag, N. Kalkers, L. Kaya, 2019, Multiple sclerosis.

Cytokine producing CD8+ T cells are correlated to MRI features of tissue destruction in MS

F. Barkhof, C. Polman, B. Uitdehaag, 2003, Journal of Neuroimmunology.

The patient's perception of a (reliable) change in the Multiple Sclerosis Functional C omposite

C. Polman, G. Cutter, N. Kalkers, 2004, Multiple sclerosis.

Motor evoked potential: A reliable and objective measure to document the functional consequences of multiple sclerosis? Relation to disability and MRI

R. Strijers, J. Geurts, N. Kalkers, 2007, Clinical Neurophysiology.

Don’t be late! Timely identification of cognitive impairment in people with multiple sclerosis: a study protocol

M. Schoonheim, H. Hulst, N. Kalkers, 2024, BMC neurology.